Short course chemotherapy for childhood tuberculosis

Area of Science:

• Pediatric Infectious Diseases
• Public Health
• Pharmacology

Background:

• Limited published data existed on the efficacy of short-course chemotherapy (SCC) for childhood tuberculosis (TB).
• Childhood TB presents unique challenges in diagnosis and treatment adherence.
• Extrapulmonary TB is common in young children.

Purpose of the Study:

• To evaluate the safety and effectiveness of a 6-month SCC regimen in children with TB.
• To assess clinical response and adverse drug reactions to SCC in a pediatric population.
• To determine relapse rates and factors influencing treatment outcomes in childhood TB.

Main Methods:

• A prospective study conducted in Port Moresby included all children diagnosed with TB between November 1984 and November 1986.
• Children received a 6-month SCC regimen: 2 months daily rifampin, isoniazid, pyrazinamide, and streptomycin, followed by 4 months of twice-weekly rifampin and isoniazid.
• Follow-up included clinical assessment and attempted 24-month post-treatment monitoring.

Main Results:

• A rapid clinical response to SCC was observed in most children.
• Adverse drug reactions were infrequent (2%), primarily associated with streptomycin.
• Relapse occurred in 7 out of 373 children (1.9%), predominantly in those with irregular treatment adherence.

Conclusions:

• Short-course chemotherapy (SCC) is a safe and effective treatment option for both pulmonary and extrapulmonary tuberculosis in children.
• The SCC regimen demonstrated good tolerability and a low relapse rate in this cohort.
• Adherence to treatment is crucial for successful outcomes in childhood TB management.